28-Sep-2026
TipRanks (Mon, 28-Sep 5:34 AM ET)
Mereo BioPharma’s Alvelestat Deal and Improved Cash Runway Pave Path for 2027 Growth
Market Chameleon (Tue, 11-Aug 5:55 AM ET)
Mereo BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Highlights
Globe Newswire (Tue, 11-Aug 8:15 AM ET)
PRNewswire (Tue, 11-Aug 8:01 AM ET)
Globe Newswire (Tue, 11-Aug 8:00 AM ET)
Mereo BioPharma Extends Cash Runway to Mid-2027 Amid Mixed Setrusumab Phase 3 Results
Market Chameleon (Mon, 12-Jan 5:31 AM ET)
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
Mereo Biopharma Group PLC - American Depositary Shares trades on the NASDAQ stock market under the symbol MREO.
As of September 28, 2026, MREO stock price was flat at $0.37 with 1,654,218 million shares trading.
MREO has a beta of 2.80, meaning it tends to be more sensitive to market movements. MREO has a correlation of 0.04 to the broad based SPY ETF.
MREO has a market cap of $59.06 million. This is considered a Micro Cap stock.
Last quarter Mereo Biopharma Group PLC - American Depositary Shares reported $0 in Revenue and -$.01 earnings per share. This fell short of revenue expectation by $-863,830 and met earnings estimates .
In the last 3 years, MREO traded as high as $5.02 and as low as $.20.
MREO has underperformed the market in the last year with a return of -79.1%, while SPY returned +17.5%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in MREO shares. However, MREO has outperformed the market in the last 3 month and 2 week periods, returning +22.9% and +32.1%, while SPY returned +4.5% and +0.4%, respectively. This indicates MREO has been having a stronger performance recently.
MREO support price is $.35 and resistance is $.39 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MREO shares will trade within this expected range on the day.
